Infliximab is a monoclonal
anti-TNF antibody.
Ezetimibe acts
by prevent cholesterol absorption from the
small intestine. Typically it reduces LDL-cholesterol
by approximately 20%, triglycerides by up to 5% and raises
HDL-cholesterol by approximately 5%.
Ezetimibe is currently licensed
for use in combination with a statin in patients who fail to reach desired lipid profiles
or as monotherapy in patients
intolerant to a statin.
No comments:
Post a Comment